Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Hot-Melt-Extruded Efavirenz
NCT03886766Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University Hospital Basel. Primary endpoints: Area Under the Curve at 72 hours, Relative Bioavailability at 72 hours and 4 more. Started Apr 2019; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03886766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886766.